Comparative review

Though we’ve had great success with Sirtex and Cellestis, value investors normally shudder at the thought of owning biotech stocks. The chief difference between this pair and Mesoblast and Prima Biomed is that they were profitable. Regenerative medicine is the ‘process of replacing or regenerating human cells, tissues or organs to restore or establish normal function.’ Mesoblast plans on using stem cells to treat myriad diseases and ailments and is being touted as the next CSL. Despite burning through piles of cash each year the company has a breathtaking market value of $2bn, but until Mesoblast turns profitable we’d...

Though we’ve had great success with Sirtex and Cellestis, value investors normally shudder at the thought of owning biotech stocks. The chief difference between this pair and Mesoblast and Prima Biomed is that they were profitable.

{{content.question}}

{{ twilioFailed ? 'SMS Code Failed to Send…' : 'SMS Code Sent…' }}

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa
Mastercard

The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device


Register as a new member

(using a different email)

Related Articles